export const mockBlogPosts = [
    {
        id: '1',
        slug: 'navigating-fda-guidance-gene-therapy-2025',
        title: 'Navigating New FDA Guidelines for Gene Therapy Approvals: A 2025 Outlook',
        excerpt: 'The FDA has recently updated its framework for gene therapy products, emphasizing long-term safety monitoring and manufacturing consistency. Here is what biotech sponsors need to know to prevent clinical holds.',
        content: 'The landscape of gene therapy regulation is shifting rapidly as the FDA adapts to the unique challenges of durable treatments. In its latest guidance, the agency has placed renewed emphasis on Chemistry, Manufacturing, and Controls (CMC) as a critical bottleneck for approval. Sponsors are now expected to demonstrate potency assay validation much earlier in the clinical development lifecycle than previously required.\n\nFurthermore, the long-term follow-up requirements have been clarified, with a risk-based approach allowing for some flexibility in the duration of monitoring. This change is significant for developers of non-integrating viral vectors, who may now face reduced post-market surveillance burdens compared to integrating vector therapies. Our analysis suggests that proactive engagement with the CBER office during the pre-IND phase is more critical than ever to align on these surrogate endpoints.\n\nFor companies targeting rare diseases, the "Consultation for Clinical Studies of Orphan Drugs" program remains an underutilized pathway. By leveraging real-world evidence (RWE) to supplement small clinical trial cohorts, sponsors can robustly demonstrate efficacy. Mevoq has successfully guided three gene therapy candidates through this accelerated pathway in the last 18 months.',
        category: 'Regulatory Strategy',
        tags: ['FDA', 'Gene Therapy', 'CMC', 'Clinical Trials', 'Orphan Drugs'],
        featured_image: 'https://placehold.co/1200x630/001F3F/FFF?text=Gene+Therapy+Guidelines',
        author: 'Dr. Sarah Chen',
        author_role: 'Senior Regulatory Consultant',
        published: true,
        published_at: '2025-10-15T09:00:00Z',
        updated_at: '2025-10-15T09:00:00Z'
    },
    {
        id: '2',
        slug: 'avoiding-clinical-holds-ind-submissions',
        title: 'Top 5 Reasons for FDA Clinical Holds on IND Submissions in 2025',
        excerpt: 'Clinical holds can delay drug development by months or years. We analyze the most common triggers for FDA holds in the current regulatory climate and how to avoid them.',
        content: 'An FDA clinical hold is a sponsor’s worst nightmare, immediately halting all study activities. Our review of 2025 enforcement actions reveals that insufficient toxicology data remains the number one cause of full clinical holds. Specifically, the FDA is increasingly scrutinizing the relevance of animal models in relation to human dose selection, particularly for biologics.\n\nSecondly, Investigator Brochures (IB) that fail to clearly communicate risk mitigation strategies are a frequent sticking point. The agency expects a transparent summary of all safety signals, not just a data dump of preclinical results. Quality of the drug substance is the third major factor; impurities that are not adequately characterized or qualified according to ICH Q3 guidelines will trigger an immediate red flag.\n\nIt is worth noting that "partial holds" are becoming a more common regulatory tool, allowing some arms of a trial to proceed while others are paused. While less devastating than a full hold, they still signal a lack of confidence from the review division. To mitigate this risk, Mevoq recommends a rigorous mock-audit of the entire IND package prior to submission, simulating the FDA review process to catch these gaps early.',
        category: 'Compliance',
        tags: ['IND', 'FDA', 'Clinical Holds', 'Toxicology', 'Risk Management'],
        featured_image: 'https://placehold.co/1200x630/0052CC/FFF?text=Clinical+Holds',
        author: 'Dr. Ashok Shah',
        author_role: 'Founder & Chief Regulatory Officer',
        published: true,
        published_at: '2025-09-22T14:30:00Z',
        updated_at: '2025-09-22T14:30:00Z'
    },
    {
        id: '3',
        slug: 'ectd-4-0-implementation-timeline',
        title: 'Preparing for eCTD v4.0: Mandatory Implementation Timelines',
        excerpt: 'The transition to eCTD v4.0 is approaching. Learn about the new bidirectional communication features and how to upgrade your submission publishing systems.',
        content: 'Electronic Common Technical Document (eCTD) version 4.0 represents the most significant update to submission standards in over a decade. Unlike v3.2.2, which was largely a one-way street from sponsor to agency, v4.0 enables two-way communication. This allows health authorities to send queries and requests for information (RFIs) directly within the submission sequence hierarchy, greatly streamlining the review lifecycle.\n\nSponsors must be aware that the implementation timelines differ by region. The FDA is currently in a voluntary pilot phase, with mandatory adoption expected for certain submission types by late 2026. The EMA and PMDA (Japan) are following similar but slightly staggered schedules. A key technical change is the move from XML to HL7 FHIR standards, requiring significant updates to publishing software.\n\nWaiting until the deadline is a risky strategy. We advise clients to run a pilot submission using v4.0 standards for a minor amendment or annual report well before the mandatory cutoff. This "soft launch" approach allows your regulatory operations team to troubleshoot validation errors without jeopardizing a critical NDA or BLA approvals path.',
        category: 'FDA Updates',
        tags: ['eCTD', 'Regulatory Operations', 'Submissions', 'FDA', 'EMA'],
        featured_image: 'https://placehold.co/1200x630/1DD1A1/001F3F?text=eCTD+v4.0',
        author: 'Michael Torres',
        author_role: 'Director of Regulatory Operations',
        published: true,
        published_at: '2025-08-10T11:15:00Z',
        updated_at: '2025-08-10T11:15:00Z'
    },
    {
        id: '4',
        slug: 'orphan-drug-designation-benefits',
        title: 'Maximizing the Benefits of Orphan Drug Designation',
        excerpt: 'Beyond tax credits, Orphan Drug Designation offers strategic advantages including seven years of market exclusivity. Here is how to construct a winning ODD application.',
        content: 'Securing Orphan Drug Designation (ODD) is a pivotal milestone for biotechs developing treatments for rare diseases (defined in the US as affecting fewer than 200,000 people). The financial incentives are well-known: a 25% tax credit on clinical research costs and waiver of the PDUFA user fee (worth over $3 million).\n\nHowever, the strategic benefits often outweigh the financial ones. Seven years of market exclusivity upon approval provides a powerful shield against generic competition, which is crucial for maximizing ROI on niche therapies. Additionally, the designation opens doors for increased regulatory assistance from the Office of Orphan Products Development (OOPD). \n\nThe key to a successful ODD application lies in the "plausible hypothesis." You do not need to prove efficacy at this stage, but you must demonstrate a scientific rationale for why the drug is likely to be effective in the specific rare disease. Mevoq specializes in drafting these rationales, leveraging mechanism-of-action data to build a compelling case even with limited clinical evidence.',
        category: 'Regulatory Strategy',
        tags: ['Orphan Drugs', 'Market Exclusivity', 'Rare Disease', 'FDA'],
        featured_image: 'https://placehold.co/1200x630/003BA3/FFF?text=Orphan+Drug+Designation',
        author: 'Dr. Sarah Chen',
        author_role: 'Senior Regulatory Consultant',
        published: true,
        published_at: '2025-07-05T08:45:00Z',
        updated_at: '2025-07-05T08:45:00Z'
    },
    {
        id: '5',
        slug: 'case-study-accelerated-approval-oncology',
        title: 'Case Study: Achieving Accelerated Approval for a Novel Oncology Agent',
        excerpt: 'How Mevoq helped a mid-sized pharma client secure FDA Accelerated Approval using a surrogate endpoint, shaving 3 years off their development timeline.',
        content: 'In 2024, Mevoq partnered with a client developing a novel targeted therapy for metastatic non-small cell lung cancer (NSCLC). The standard approval pathway would have required overall survival (OS) data, necessitating a trial duration of 5+ years. Our strategy focused on validating Objective Response Rate (ORR) as a surrogate endpoint reasonably likely to predict clinical benefit.\n\nWe facilitated three Critical Path Innovation Meetings (CPIM) with the FDA to align on the statistical analysis plan for the single-arm Phase 2 trial. By demonstrating the high correlation between ORR and OS in historical control data, we secured the agency’s agreement to accept the surrogate endpoint.\n\nThe result was an NDA submission 36 months earlier than originally projected. The drug received Accelerated Approval, allowing the client to generate revenue while confirming clinical benefit in a post-marketing confirmatory trial. This case highlights the value of aggressive, scientifically-backed regulatory negotiation.',
        category: 'Case Studies',
        tags: ['Oncology', 'Accelerated Approval', 'Case Study', 'Clinical Strategy'],
        featured_image: 'https://placehold.co/1200x630/001F3F/1DD1A1?text=Oncology+Case+Study',
        author: 'Dr. Ashok Shah',
        author_role: 'Founder & Chief Regulatory Officer',
        published: true,
        published_at: '2025-06-12T10:00:00Z',
        updated_at: '2025-06-12T10:00:00Z'
    },
    {
        id: '6',
        slug: 'post-approval-compliance-checklist',
        title: 'The Essential Post-Approval Compliance Checklist for NDA Holders',
        excerpt: 'Approval is just the beginning. Maintain your license and avoid warning letters with this comprehensive checklist for CMC changes and Annual Reports.',
        content: 'Receiving an NDA approval letter is a moment of triumph, but it immediately triggers a new set of obligations. Many sponsors, especially smaller ones, underestimate the rigor of post-marketing requirements (PMRs) and commitments (PMCs). Failure to meet these milestones can result in public "Failure to Respond" letters or even withdrawal of approval.\n\nPrimary compliance focus areas must include the Annual Report (due within 60 days of the approval anniversary), quarterly safety reports (PADERs or PSURs), and strict adherence to the drug advertising and promotion regulations (OPDP). CMC changes are another frequent pitfall; sponsors must correctly categorize changes as CBE-0, CBE-30, or Prior Approval Supplements (PAS) based on risk.\n\nMevoq provides a "Compliance Watch" service that manages this entire lifecycle. We recently helped a client remediate a backlog of overdue Annual Reports, successfully negotiating with the FDA to avoid a Warning Letter by demonstrating a corrected and robust quality system.',
        category: 'Compliance',
        tags: ['Post-Marketing', 'Compliance', 'CMC', 'Pharmacovigilance'],
        featured_image: 'https://placehold.co/1200x630/4CAF50/FFF?text=Compliance+Checklist',
        author: 'Mr. Manish Purohit',
        author_role: 'VP Quality & Compliance',
        published: true,
        published_at: '2025-05-20T13:20:00Z',
        updated_at: '2025-05-20T13:20:00Z'
    }
];

export const mockServices = [
    {
        id: '1',
        title: "Regulatory Strategy & Planning",
        description: "Navigate complex regulatory pathways with confidence. We design optimal strategies for global market access.",
        icon: "map-pin",
        features: [
            "Regulatory pathway assessment",
            "Meeting preparation (FDA, EMA, PMDA)",
            "Risk mitigation strategies",
            "Global harmonization planning",
            "Labeling & artwork",
            "Technical file preparations",
            "Clinical evaluation reports"
        ],
        case_study_snippet: "Helped biotech company achieve FDA breakthrough designation"
    },
    {
        id: '2',
        title: "Regulatory Documentation",
        description: "Expert preparation of submission-ready regulatory documents that meet global standards.",
        icon: "file-text",
        features: [
            "IND/NDA/BLA preparation",
            "CTD/eCTD compilation",
            "DMFs, ASMFs, CEPs, CADIFAs, etc."
        ],
        case_study_snippet: "Created complete NDA package in 4 months vs. industry average of 8"
    },
    {
        id: '3',
        title: "Quality & Compliance",
        description: "Build robust quality systems that pass inspections and ensure sustainable compliance.",
        icon: "shield-check",
        features: [
            "Quality system design & remediation",
            "GMP/GCP compliance audits",
            "Inspection readiness",
            "CAPA effectiveness review"
        ],
        case_study_snippet: "Successful GMP inspections by regulatory authorities for our clients"
    },
    {
        id: '4',
        title: "Medical & Scientific Writing",
        description: "Clear, compelling regulatory narratives that accelerate review and approval.",
        icon: "pen-tool",
        features: [
            "Clinical study reports",
            "Regulatory responses",
            "Scientific publications",
            "Patient-facing materials"
        ],
        case_study_snippet: "Successfully addressed the queries raised by ethics committee"
    },
    {
        id: '5',
        title: "Risk Management",
        description: "Proactive identification and mitigation of regulatory and quality risks.",
        icon: "alert-triangle",
        features: [
            "Risk assessments",
            "Gap analysis",
            "Deviation investigation",
            "Change control evaluation"
        ],
        case_study_snippet: "Successful vendor approval through nitrosamine impurities compliance"
    },
    {
        id: '6',
        title: "Administrative Support",
        description: "Streamline your compliance operations with expert administrative assistance.",
        icon: "folder",
        features: [
            "Document management",
            "Submission tracking",
            "Regulatory intelligence",
            "Process optimization",
            "US authorized agent",
            "US FDA administrative activities",
            "Accreditation certification applications"
        ],
        case_study_snippet: "Reduced administrative burden by 60% for mid-size pharma"
    }
];

export const mockTestimonials = [
    {
        id: '1',
        name: "Dr. Sarah Chen",
        role: "VP Regulatory Affairs",
        company: "BioGenix Therapeutics",
        content: "Mevoq cut our FDA submission timeline by 40%. Their expertise in regulatory strategy is unmatched. We launched 3 months ahead of schedule.",
        rating: 5
    },
    {
        id: '2',
        name: "Marcus Williams",
        role: "Chief Scientific Officer",
        company: "PharmaTech Solutions",
        content: "The team's deep regulatory knowledge and proactive approach saved us from costly compliance issues. Best consulting investment we've made.",
        rating: 5
    },
    {
        id: '3',
        name: "Dr. Amelia Rodriguez",
        role: "Director of Quality",
        company: "MedLife Innovations",
        content: "Working with Mevoq felt like having an extension of our own team. Their documentation expertise is exceptional.",
        rating: 5
    }
];

export const mockTeam = [
    {
        id: '1',
        name: "Dr. Ashok Shah",
        role: "Founder & Chief Regulatory Officer",
        bio: "Former FDA reviewer with 15+ years in pharmaceutical regulation. Led 200+ successful drug approvals.",
        expertise: ["FDA Strategy", "CMC Review", "IND/NDA Submissions"],
        avatar_url: null
    },
    {
        id: '2',
        name: "Mr. Manish Purohit",
        role: "VP Quality & Compliance",
        bio: "Quality systems expert with Big Pharma and biotech experience. Specializes in remediation and inspection readiness.",
        expertise: ["Quality Systems", "GMP Compliance", "Inspection Management"],
        avatar_url: null
    },
    {
        id: '3',
        name: "Mr. Shailesh Shah",
        role: "Director of Regulatory Writing",
        bio: "Medical writer and regulatory affairs specialist. Authored regulatory documents for 50+ global submissions.",
        expertise: ["Medical Writing", "Regulatory Documentation", "Global Submissions"],
        avatar_url: null
    }
];

export const mockStats = {
    successful_submissions: 50,
    project_weeks_saved: 500,
    years_experience: 25,
    countries_served: 15
};
